NeuBase Therapeutics, Inc. (NBSE) Financials

NBSE Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 18.6 million 9.5 million
2023-06-30 22.3 million 11.1 million
2023-03-31 21.5 million 7.0 million
2022-12-31 25.6 million 7.4 million

NBSE Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -2.0 million -292343
2023-06-30 -3.6 million 245012
2023-03-31 -3.5 million 316689
2022-12-31 -5.7 million -509072

NBSE Net Income

No data available :(

NBSE Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 12.6 million - 5.3 million
2023-06-30 14.7 million - 5.5 million
2023-03-31 13.8 million - 5.6 million
2022-12-31 17.4 million - 5.8 million

NBSE Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 2.8 million
2023-06-30 1.7 million
2023-03-31 1.7 million
2022-12-31 1.7 million

NBSE Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 - 387564 1.2 million -
2023-06-30 6 1.3 million 2.4 million -
2023-03-31 13447 1.2 million 2.9 million -
2022-12-31 49844 1.4 million 2.6 million -

NBSE Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 250246
2023-06-30 - 303975
2023-03-31 - 300473
2022-12-31 - -

NBSE

Price: $0.40

52 week price:
0.39
5.40

Earnings Per Share: -18.60 USD

P/E Ratio: -0.04

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 97523

Market Capitalization: 1.5 million

Links: